IL17A and psoriasis: In the separate comparative analyses, the results showed no significant differences in the rate of SARS-CoV-2 infection in psoriasis patients receiving topical therapies, phototherapy, apremilast, dimetil-fumarate, acitretin, methotrexate or cyclosporine alone compared to those receiving IL-17 inhibitors (Figure S1).